Abstract
Anthracyclines such as doxorubicin, epirubicin, and daunorubicin are among the most active cytoxic agents for treatment of a wide variety of solid tumors and hematological malignancies. The downside associated with chronic administration of anthracyclines is the induction of cardiomyopathy and congestive heart failure, usually refractory to common treatments. Anthracycline liposomal formulations are currently the best-known alternatives to improve the index and spectrum of anticancer activity of these drugs and decrease their cardiotoxicity. In the current target therapy era in oncology, anthracyclines increase the antitumor effects in more than additive fashion, being excellent partners for other active agents like taxanes and trastuzumab. It is important to note, however, that the enhanced antitumor activity of these combination therapies is often accompanied with increased cardiotoxicity. The issue of anthracycline cardiotoxicity has not been solved so far and it is also important to stress the current lack of proper prevention and treatment strategies.
Similar content being viewed by others
References
De Vita, V. T., & Chu, E. (2003). Drug development. Principles and Practice in Oncology. Philadelphia, Lippincott, 354.
Weiss, R. B., Sarosy, G., Clagett-Carr, K., Russo, M., & Leyland-Jones, B. (1986). Anthracycline analogs: The past, present, and future. Cancer Chemotherapy Pharmacology, 18, 185–197.
Verweij, J., & Kees Nooter (2002). Principles of Chemoterapy. Oxford, 564.
Hortobagyi, G. N. (1997). Anthracyclines in the treatment of cancer: An overview. Drugs, 54(Suppl 4), 1–7.
Zunino, F., & Capranico, G. (1992). DNA topisomerasas II as the primary target of antitumoral anthracyclines. Anticancer Drug Designs, 5, 307–317.
Doroshow, J. (2001). Anthracyclines and anthracenediones. Cancer chemotherapy & Biotherapy, 13, 500–537.
Friche, E., Skovsgaardt, T., & Nissen, J. I. (1989). Anthracycline resistance. Acta Oncologia, 28, 877–881.
Buzdar, A. U. (2006). Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer. Journal of Clinical Oncology, 24, 2409–2411.
Bonadona, G., & DeLena, M. (1975). Combination usage of Adriamycin (NSC-123127) in malignant Lymphoma. Cancer Chemotherapy Reports, 6, 381–388.
Sledge, G. W., Neuberg, D., & Bernardo, P., et al (2003). Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). Journal of Clinical Oncology, 21(4), 588–592.
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: Molecular advances and pharmacology developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56(2), 185–229.
Steinherz, L. J., Steinherz, P. G., Tan, C. T. C., & Heller, G. (1991). Cardiac toxicity 4 to 20 years after completing anthracyclines therapy. JAMA 266, 1672–1677.
Von Hoff, D. D., Layard, M. W., & Basa, P (1979). Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine, 91, 710–717.
Seidman, A., Hudis, C., & Pierri, M. K. (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. Journal of Clinical Oncology, 20, 1215–1221.
Singal, P. K. (1998) Adryamicin cardiomiopathy. The New England Journal of Medicine, 339, 900–905.
Elliot, P. (2006). Pathogenesis of cardiotoxicity induced by anthracyclines. Seminars in Oncology, 33, S2–S7.
Marty, M., Espie, M., Llombart, A., Monnier, A., Rapoport, B.L., & Stahalova, V., Dexrazoxane Study Group. (2006). Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Annals of Oncology, 17, 614–622.
Cvtovic, R. C., & Scott, L. J. (2005). Dexrazoxane: A review of its use for cardioprotection during anthracycline chemotherapy. Drugs, 65, 1005–1012.
Northfelt, D. W., Dezube, B. J., & Thommes, J. A., et al (1998). Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: Results of a randomized phase III clinical trial. Journal of Clinical Oncology, 16, 2445–2451.
Working, P. K., Newman, M. S., & Huang, S. K., et al (1994). Pharmacokinetics biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth liposomes (Doxil). Journal of Liposome Research, 4, 667–687.
Cheung, T. W., Remick, S. C., Azarnia, N., Proper, J. A., Barrueco, J. R., & Dezube, B. J. (1999). AIDS-related Kaposi’s sarcoma: A phase II study of liposomal doxorubicin. The TLC D-99 Study Group. Clinical Cancer Research, 5, 3432–3437.
Sturzl, M., Zietz C., Eisenburg, B., Goebel, F. D., Gillitzer, R., Hofschneider, P. H., & Bogner, J. R. (1994). Liposomal doxorubicin in the treatment of AIDS-associated Kaposi’s sarcoma: Clinical, histological and cell biological evaluation. Research in Virology, 145, 261–269.
Johnston, S. R. D., & Gore, M. E. (2001). Caelyx: Phase II studies in ovarian cancer. European Journal of Cancer, 37, S8–S14.
Coleman, R. E., Biganzoli, L., & Canney, P. et al (2006). A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). European Journal of Cancer, 42, 882–887.
Lyass, O., Uziely, B., & Ben-Yosef, R. et al (2000). Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer, 89, 1037–1047.
O´Byrne, K. J., Thomas, A. L., & Sharma, R. A., et al (2002). A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. British Journal of Cancer, 87, 15–20.
Valero, V., & Hortobagyi, G. N. (2003). Are anthracyclines-taxane regimens the new standard of care in the treatment of metastatic breast cancer? Journal of Clinical Oncology, 21, 959–962.
Giani, L., Vigano, L., & Locatelli, A., et al (1997). Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. Journal of Clinical Oncology, 15, 1906–1915.
Minotti, G., Saponiero, A., & Licata, S., et al (2001). Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clinical Cancer Research, 7, 1511–1515.
Nabholtz, J. M., Falkson, C., & Campos, D., et al (2003). Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. Journal of Clinical Oncology, 21, 968–975.
Feldman, A. M., Lorell, B. H., & Reiss, S. E. (2000). Trastuzumab in the treatment of metastatic breast cancer: Anticancer therapy versus cardiotoxicity. Circulation, 102, 272–274.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cortés-Funes, H., Coronado, C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 7, 56–60 (2007). https://doi.org/10.1007/s12012-007-0015-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12012-007-0015-3